Anebulo Pharmaceuticals, Inc. - קפיטליזציית שוק ANEB

Anebulo Pharmaceuticals (ANEB) creates unique antidotes for cannabinoid intoxication, securing a monopoly position through its patents. The business targets the B2B segment of emergency departments for the therapy of acute psychosis. A clear inventory system and streamlined component delivery guarantee development stability. The asset's market capitalization is 0.01. The asset's price trajectory is illustrated in the chart below.

When screening for issuer reliability, enterprise value serves as the key filter. The market capitalization of a company is calculated as the product of the current share price and the total number of outstanding securities. For Anebulo Pharmaceuticals (ANEB), this metric reflects a speculative valuation of antidote potential in the absence of revenue and positive FCF. The market capitalization trend of Anebulo Pharmaceuticals (ANEB) demonstrates the asset's market weight amid high R&D expenditures.